SuperworthBeOne Medicines forward PE ONC
Share price divided by analysts' consensus earnings for the next twelve months, since 2025.
- Today, Oct 23, 2026
- 48.1×
- Peer median
- 26.7×
BeOne Medicines' forward PE is 48.1× as of Oct 23, 2026.
The median for 10 biotech stocks of a similar size is 26.7×.
Forward PE over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 48.1× | 37.4× | 62.9× |
| 2025 | 54.2× | 54.2× | 142× |
Against its peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.
| Company | Forward PE |
|---|---|
| ONCBeOne Medicines | 48.1× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| UTHRUnited Therapeutics | 22.0× |
| INCYIncyte | 49.5× |
| REGNRegeneron Pharmaceuticals | 12.6× |
| EXELExelixis | n/m |
| NBIXNeurocrine Biosciences | n/m |
| HALOHalozyme Therapeutics | n/m |
| VRTXVertex Pharmaceuticals | 27.0× |
| TECHBIO-TECHNE | n/m |
| RGENRepligen | n/m |
| Peer median | 26.7× |
Where BeOne Medicines ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on BeOne Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.